Sell Ranbaxy Labs; target of Rs 355: PINC Research

40083 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Sell Ranbaxy Labs; target of Rs 355: PINC Research

PINC Research bearish on Ranbaxy Labs and has recommended sell rating on the stock with a target of Rs 355 in its January 27, 2012 research report.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Buy Shree Cements; tgt of Rs 2608: Networth Stock Broking Buy Polaris Tech; target of Rs 202: BP Equities Buy Ajanta Pharma; target of Rs 409: Nirmal Bang ALSO READ See previous views by PINC Research See what other Experts & Brokerages are saying about Ranbaxy Labs See messages about Ranbaxy Labs Ranbaxy Labs BSE | NSE 01/06/12 Are Mutual Funds betting on Ranbaxy Labs?

PINC Research bearish on Ranbaxy Labs and has recommended sell rating on the stock with a target of Rs 355 in its January 27, 2012 research report.

"The US DOJ has filed the consent decree against Ranbaxy in the US district court of Maryland. The consent decree will address outstanding cGMP and data integrity issues at Ranbaxy's Paonta Sahib, Batamandi, Dewas and Gloversville facility. Ranbaxy's Paonta Sahib, Batamandi and Dewas facilities are under import alert while the company has closed its Gloversville facility. US DOJ and USFDA had found following issues with Ranbaxy's manufacturing facilities 1) failure to keep written records showing that drugs had been manufactured properly 2) failure to investigate evidence indicating that drugs did not meet their specifications 3) failure to adequately separate the manufacture of penicillin drugs from non-penicillin drugs in order to prevent cross-contamination 4) failure to have adequate procedures to prevent contamination of sterile drugs and 5) inadequate testing of drugs to ensure that they kept their strength and effectiveness until their expiration date."

"Given the issues involved at the aforesaid facilities and the delay in entering consent decree with the USFDA we expect the clearance of the facilities to be long time driven and costly process (over and above the provision of USD 500mn made) which would impact the base operating margins of the company. Although the names of FTFs surrendered have not been disclosed, we expect it to be generic Provigil, Diovan and Valcyte contributing sales to the tune of USD186mn and NPV of Rs12 per share. The stock is currently trading at 29.2x and 20.3x its CY12E and CY13E recurring earnings respectively. We continue with our negative outlook and downgrade the stock to 'Sell'. We value the core business at Rs329/share (22x one year forward recurring earnings), FTF pipeline at Rs81/share and reduce Rs55/share for the penalty provision resulting in revised SOTP based target price of Rs 355," says PINC Research report.

Public holding more than 90% in Indian cos

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment